{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T18:23:32Z","timestamp":1792002212260,"version":"4.4.0"},"reference-count":93,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"am","delay-in-days":334,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100006108","name":"NCATS","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006108","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.com.au","thrombosisresearch.com","clinicalkey.es","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Thrombosis Research"],"published-print":{"date-parts":[[2024,9]]},"DOI":"10.1016\/j.thromres.2024.109097","type":"journal-article","created":{"date-parts":[[2024,7,23]],"date-time":"2024-07-23T06:48:03Z","timestamp":1721717283000},"page":"109097","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"special_numbering":"C","title":["Anticoagulant therapy in renal insufficiency theme: Anticoagulation in complex situations"],"prefix":"10.1016","volume":"241","author":[{"given":"Anna L.","family":"Parks","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Scott M.","family":"Stevens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Scott C.","family":"Woller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.thromres.2024.109097_bb0005","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.kisu.2021.11.003","article-title":"Epidemiology of chronic kidney disease: an update 2022","volume":"12","author":"Kovesdy","year":"2022","journal-title":"Kidney International Supplements"},{"issue":"3","key":"10.1016\/j.thromres.2024.109097_bb0010","doi-asserted-by":"crossref","first-page":"181","DOI":"10.7326\/M19-0087","article-title":"Benefits and harms of oral anticoagulant therapy in chronic kidney disease","volume":"171","author":"Ha","year":"2019","journal-title":"Ann Intern Med. American College of Physicians"},{"issue":"11","key":"10.1016\/j.thromres.2024.109097_bb0015","first-page":"1157","article-title":"Cardiovascular disease in chronic kidney disease","volume":"143","author":"Jankowski","year":"2021","journal-title":"Circulation. American Heart Association"},{"issue":"9844","key":"10.1016\/j.thromres.2024.109097_bb0020","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1016\/S0140-6736(12)60572-8","article-title":"Risk of coronary events in people with chronic kidney disease compared with those with diabetes: a population-level cohort study","volume":"380","author":"Tonelli","year":"2012","journal-title":"The Lancet. Elsevier"},{"issue":"1","key":"10.1016\/j.thromres.2024.109097_bb0025","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1681\/ASN.2007030308","article-title":"Chronic kidney disease increases risk for venous thromboembolism","volume":"19","author":"Wattanakit","year":"2008","journal-title":"J Am Soc Nephrol."},{"issue":"23","key":"10.1016\/j.thromres.2024.109097_bb0030","doi-asserted-by":"crossref","first-page":"1735","DOI":"10.1161\/CIRCULATIONAHA.121.054990","article-title":"Apixaban for patients with atrial fibrillation on hemodialysis: a multicenter randomized controlled trial","volume":"146","author":"Pokorney","year":"2022","journal-title":"Circulation"},{"issue":"4","key":"10.1016\/j.thromres.2024.109097_bb0035","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1161\/CIRCULATIONAHA.122.062779","article-title":"A randomized controlled trial comparing apixaban with the vitamin K antagonist phenprocoumon in patients on chronic hemodialysis: the AXADIA-AFNET 8 study","volume":"147","author":"Reinecke","year":"2023","journal-title":"Circulation"},{"issue":"1","key":"10.1016\/j.thromres.2024.109097_bb0040","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1001\/jamainternmed.2015.6102","article-title":"Representation of patients With kidney disease in trials of cardiovascular interventions: an updated systematic Review","volume":"176","author":"Konstantinidis","year":"2016","journal-title":"JAMA Intern. Med."},{"issue":"26","key":"10.1016\/j.thromres.2024.109097_bb0045","doi-asserted-by":"crossref","first-page":"2499","DOI":"10.1056\/NEJMoa1007903","article-title":"Oral rivaroxaban for symptomatic venous thromboembolism","volume":"363","author":"EINSTEIN Investigators","year":"2010","journal-title":"N. Engl. J. Med."},{"issue":"8","key":"10.1016\/j.thromres.2024.109097_bb0050","first-page":"711","article-title":"Apixaban to prevent venous thromboembolism in patients with cancer","volume":"380","author":"Carrier","year":"2019","journal-title":"New England Journal of Medicine. Massachusetts Medical Society"},{"issue":"9","key":"10.1016\/j.thromres.2024.109097_bb0055","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1056\/NEJMoa1007432","article-title":"Apixaban in patients with atrial fibrillation","volume":"364","author":"Connolly Stuart","year":"2011","journal-title":"N. Engl. J. Med."},{"issue":"11","key":"10.1016\/j.thromres.2024.109097_bb0060","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1056\/NEJMoa1107039","article-title":"Apixaban versus warfarin in patients with atrial fibrillation","volume":"365","author":"Granger","year":"2011","journal-title":"New England Journal of Medicine"},{"issue":"11","key":"10.1016\/j.thromres.2024.109097_bb0065","doi-asserted-by":"crossref","first-page":"1469","DOI":"10.1001\/jamainternmed.2019.2431","article-title":"Perioperative Management of Patients With Atrial Fibrillation Receiving a Direct Oral anticoagulant","volume":"179","author":"Douketis","year":"2019","journal-title":"JAMA Intern. Med."},{"issue":"13","key":"10.1016\/j.thromres.2024.109097_bb0070","first-page":"1206","article-title":"Dabigatran versus Warfarin in patients with mechanical heart valves","volume":"369","author":"Eikelboom","year":"2013","journal-title":"New England Journal of Medicine. Massachusetts Medical Society"},{"issue":"8","key":"10.1016\/j.thromres.2024.109097_bb0075","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1056\/NEJMoa1113697","article-title":"Extended use of dabigatran, warfarin, or placebo in venous thromboembolism","volume":"368","author":"Schulman","year":"2013","journal-title":"N. Engl. J. Med."},{"issue":"7","key":"10.1016\/j.thromres.2024.109097_bb0080","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1056\/NEJMoa1711948","article-title":"Edoxaban for the treatment of cancer-associated venous thromboembolism","volume":"378","author":"Raskob","year":"2018","journal-title":"N. Engl. J. Med."},{"issue":"10","key":"10.1016\/j.thromres.2024.109097_bb0085","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1056\/NEJMoa1009638","article-title":"Rivaroxaban versus warfarin in nonvalvular atrial fibrillation","volume":"365","author":"Patel","year":"2011","journal-title":"N. Engl. J. Med."},{"issue":"22","key":"10.1016\/j.thromres.2024.109097_bb0090","doi-asserted-by":"crossref","first-page":"2093","DOI":"10.1056\/NEJMoa1310907","article-title":"Edoxaban versus warfarin in patients with atrial fibrillation","volume":"369","author":"Giugliano","year":"2013","journal-title":"New England Journal of Medicine"},{"issue":"9","key":"10.1016\/j.thromres.2024.109097_bb0095","doi-asserted-by":"crossref","first-page":"604","DOI":"10.7326\/0003-4819-150-9-200905050-00006","article-title":"CKD-EPI (Chronic Kidney Disease Epidemiology Collaboration). A new equation to estimate glomerular filtration rate","volume":"150","author":"Levey","year":"2009","journal-title":"Ann Intern Med."},{"issue":"10","key":"10.1016\/j.thromres.2024.109097_bb0100","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2020.22886","article-title":"Assessment of outcomes among patients with venous thromboembolism with and without chronic kidney disease","volume":"3","author":"Goto","year":"2020","journal-title":"JAMA Network Open"},{"issue":"11","key":"10.1016\/j.thromres.2024.109097_bb0105","first-page":"1196","article-title":"Warfarin use and the risk for stroke and bleeding in patients with atrial fibrillation undergoing dialysis","volume":"129","author":"Shah","year":"2014","journal-title":"Circulation. American Heart Association"},{"issue":"23","key":"10.1016\/j.thromres.2024.109097_bb0110","doi-asserted-by":"crossref","first-page":"2471","DOI":"10.1016\/j.jacc.2014.09.051","article-title":"Net clinical benefit of antithrombotic therapy in patients with atrial fibrillation and chronic kidney disease: a nationwide observational cohort study","volume":"64","author":"Bonde","year":"2014","journal-title":"J. Am. Coll. Cardiol."},{"issue":"15","key":"10.1016\/j.thromres.2024.109097_bb0115","first-page":"1519","article-title":"Outcomes associated with apixaban use in patients with end-stage kidney disease and atrial fibrillation in the United States","volume":"138","author":"Siontis","year":"2018","journal-title":"Circulation. American Heart Association"},{"issue":"7","key":"10.1016\/j.thromres.2024.109097_bb0120","first-page":"625","article-title":"Stroke and bleeding in atrial fibrillation with chronic kidney disease","volume":"367","author":"Olesen","year":"2012","journal-title":"New England Journal of Medicine. Massachusetts Medical Society"},{"issue":"6","key":"10.1016\/j.thromres.2024.109097_bb0125","doi-asserted-by":"crossref","first-page":"2089","DOI":"10.1111\/j.1523-1755.2005.00365.x","article-title":"Definition and classification of chronic kidney disease: a position statement from kidney disease: improving global outcomes (KDIGO)","volume":"67","author":"Levey","year":"2005","journal-title":"Kidney International. Elsevier"},{"issue":"2","key":"10.1016\/j.thromres.2024.109097_bb0130","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2021.48940","article-title":"Association of Intraindividual Difference in Estimated Glomerular Filtration Rate by Creatinine vs Cystatin C and End-stage Kidney Disease and Mortality","volume":"5","author":"Chen","year":"2022","journal-title":"JAMA Network Open"},{"issue":"10","key":"10.1016\/j.thromres.2024.109097_bb0135","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1056\/NEJMoa1214234","article-title":"Cystatin C versus creatinine in determining risk based on kidney function","volume":"369","author":"Shlipak","year":"2013","journal-title":"N Engl J Med."},{"issue":"19","key":"10.1016\/j.thromres.2024.109097_bb0140","doi-asserted-by":"crossref","first-page":"1737","DOI":"10.1056\/NEJMoa2102953","article-title":"New creatinine- and cystatin c-based equations to estimate GFR without race","volume":"385","author":"Inker","year":"2021","journal-title":"N Engl J Med."},{"issue":"12","key":"10.1016\/j.thromres.2024.109097_bb0145","doi-asserted-by":"crossref","first-page":"2994","DOI":"10.1681\/ASN.2021070988","article-title":"A unifying approach for GFR estimation: recommendations of the NKF-ASN task force on reassessing the inclusion of race in diagnosing kidney disease","volume":"32","author":"Delgado","year":"2021","journal-title":"J. Am. Soc. Nephrol."},{"issue":"7","key":"10.1016\/j.thromres.2024.109097_bb0150","doi-asserted-by":"crossref","first-page":"314","DOI":"10.3389\/fcell.2019.00314","article-title":"Unraveling cardiovascular risk in renal patients: a new take on old tale","author":"Provenzano","year":"2019","journal-title":"Front Cell Dev Biol."},{"issue":"3","key":"10.1016\/j.thromres.2024.109097_bb0155","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1016\/j.thromres.2005.03.031","article-title":"Thromboembolism and anticoagulant management in hemodialysis patients: a practical guide to clinical management","volume":"118","author":"Lo","year":"2006","journal-title":"Thromb. Res."},{"key":"10.1016\/j.thromres.2024.109097_bb0160","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.thromres.2023.04.016","article-title":"Global coagulation assays in patients with chronic kidney disease and their role in predicting thrombotic risk","volume":"226","author":"Lim","year":"2023","journal-title":"Thrombosis Research. Elsevier"},{"issue":"2","key":"10.1016\/j.thromres.2024.109097_bb0165","doi-asserted-by":"crossref","first-page":"173","DOI":"10.2215\/CJN.03170509","article-title":"Prevalence of atrial fibrillation and its predictors in nondialysis patients with chronic kidney disease","volume":"5","author":"Ananthapanyasut","year":"2010","journal-title":"Clin J Am Soc Nephrol."},{"issue":"5","key":"10.1016\/j.thromres.2024.109097_bb0170","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1038\/ki.2011.416","article-title":"The prevalence of and factors associated with chronic atrial fibrillation in Medicare\/Medicaid-eligible dialysis patients","volume":"81","author":"Wetmore","year":"2012","journal-title":"Kidney Int."},{"issue":"10","key":"10.1016\/j.thromres.2024.109097_bb0175","doi-asserted-by":"crossref","first-page":"1363","DOI":"10.1161\/CIRCULATIONAHA.108.816082","article-title":"Impact of proteinuria and glomerular filtration rate on risk of thromboembolism in atrial fibrillation: the anticoagulation and risk factors in atrial fibrillation (ATRIA) study","volume":"119","author":"Go","year":"2009","journal-title":"Circulation"},{"issue":"9","key":"10.1016\/j.thromres.2024.109097_bb0180","doi-asserted-by":"crossref","first-page":"1314","DOI":"10.2215\/CJN.04060318","article-title":"Incident atrial fibrillation and the risk of stroke in adults with chronic kidney disease: The Stockholm CREAtinine Measurements (SCREAM) Project","volume":"13","author":"Carrero","year":"2018","journal-title":"Clin J Am Soc Nephrol."},{"issue":"5","key":"10.1016\/j.thromres.2024.109097_bb0185","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1016\/j.jacc.2020.09.011","article-title":"2020 ACC Expert Consensus Decision Pathway for Anticoagulant and Antiplatelet Therapy in Patients With Atrial Fibrillation or Venous Thromboembolism Undergoing Percutaneous Coronary Intervention or With Atherosclerotic Cardiovascular Disease","volume":"77","author":"Kumbhani","year":"2021","journal-title":"Journal of the American College of Cardiology"},{"issue":"9731","key":"10.1016\/j.thromres.2024.109097_bb0190","doi-asserted-by":"crossref","first-page":"2073","DOI":"10.1016\/S0140-6736(10)60674-5","article-title":"Association of estimated glomerular filtration rate and albuminuria with all-cause and cardiovascular mortality in general population cohorts: a collaborative meta-analysis","volume":"375","author":"Chronic Kidney Disease Prognosis Consortium","year":"2010","journal-title":"Lancet"},{"issue":"5","key":"10.1016\/j.thromres.2024.109097_bb0195","doi-asserted-by":"crossref","first-page":"134","DOI":"10.5527\/wjn.v1.i5.134","article-title":"Chronic kidney disease in acute coronary syndromes","volume":"1","author":"Marenzi","year":"2012","journal-title":"World J Nephrol."},{"issue":"3","key":"10.1016\/j.thromres.2024.109097_bb0200","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1161\/01.CIR.0000114519.75433.DD","article-title":"High prevalence of peripheral arterial disease in persons with renal insufficiency: results from the National Health and Nutrition Examination Survey 1999-2000","volume":"109","author":"O\u2019Hare","year":"2004","journal-title":"Circulation"},{"issue":"16","key":"10.1016\/j.thromres.2024.109097_bb0205","first-page":"1964","article-title":"Association of mild to moderate chronic kidney disease with venous thromboembolism","volume":"126","author":"Mahmoodi","year":"2012","journal-title":"Circulation. American Heart Association"},{"issue":"5","key":"10.1016\/j.thromres.2024.109097_bb0210","first-page":"874","article-title":"Risk and complications of venous thromboembolism in dialysis patients","volume":"33","author":"Molnar","year":"2018","journal-title":"Nephrol. Dial. Transplant."},{"key":"10.1016\/j.thromres.2024.109097_bb0215","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1016\/j.phrs.2017.12.004","article-title":"Bleeding in advanced CKD patients on antithrombotic medication - A critical appraisal","volume":"129","author":"Burlacu","year":"2018","journal-title":"Pharmacol. Res."},{"issue":"1","key":"10.1016\/j.thromres.2024.109097_bb0220","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1182\/asheducation-2016.1.188","article-title":"Thrombosis and anticoagulation in the setting of renal or liver disease","volume":"2016","author":"Ribic","year":"2016","journal-title":"Hematology"},{"key":"10.1016\/j.thromres.2024.109097_bb0225","doi-asserted-by":"crossref","unstructured":"Ocak G, Rookmaaker MB, Algra A, de Borst GJ, Doevendans PA, Kappelle LJ, Verhaar MC, Visseren FL, SMART Study Group. Chronic kidney disease and bleeding risk in patients at high cardiovascular risk: a cohort study. J. Thromb. Haemost. 2018;16(1):65\u201373. 6mm.","DOI":"10.1111\/jth.13904"},{"key":"10.1016\/j.thromres.2024.109097_bb0230","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.thromres.2020.11.036","article-title":"Using oral anticoagulants among chronic kidney disease patients to prevent recurrent venous thromboembolism: A systematic review and meta-analysis","volume":"198","author":"Alhousani","year":"2021","journal-title":"Thromb. Res."},{"issue":"12","key":"10.1016\/j.thromres.2024.109097_bb0235","doi-asserted-by":"crossref","first-page":"2030","DOI":"10.1055\/s-0042-1756355","article-title":"GLORIA-AF Investigators. Clinical complexity domains, anticoagulation, and outcomes in patients with atrial fibrillation: A report from the GLORIA-AF registry phase II and III","volume":"122","author":"Romiti","year":"2022","journal-title":"Thromb. Haemost."},{"issue":"9","key":"10.1016\/j.thromres.2024.109097_bb0240","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1001\/jamaneurol.2022.2299","article-title":"Association of Chronic Kidney Disease With Risk of intracerebral hemorrhage","volume":"79","author":"Vanent","year":"2022","journal-title":"JAMA Neurol."},{"issue":"8","key":"10.1016\/j.thromres.2024.109097_bb0245","doi-asserted-by":"crossref","first-page":"596","DOI":"10.7326\/0003-4819-158-8-201304160-00004","article-title":"Risk prediction models for patients with chronic kidney disease","volume":"158","author":"Tangri","year":"2013","journal-title":"Ann Intern Med. American College of Physicians"},{"issue":"2","key":"10.1016\/j.thromres.2024.109097_bb0250","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1378\/chest.09-1584","article-title":"Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the euro heart survey on atrial fibrillation","volume":"137","author":"Lip","year":"2010","journal-title":"CHEST. Elsevier"},{"issue":"17","key":"10.1016\/j.thromres.2024.109097_bb0255","doi-asserted-by":"crossref","first-page":"2204","DOI":"10.1016\/j.jacc.2019.08.1031","article-title":"Anticoagulation in concomitant chronic kidney disease and atrial fibrillation","volume":"74","author":"Kumar","year":"2019","journal-title":"Journal of the American College of Cardiology. American College of Cardiology Foundation"},{"issue":"4","key":"10.1016\/j.thromres.2024.109097_bb0260","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1016\/j.amjmed.2013.12.003","article-title":"D-dimer to rule out pulmonary embolism in renal insufficiency","volume":"127","author":"Lindner","year":"2014","journal-title":"Am. J. Med."},{"issue":"11","key":"10.1016\/j.thromres.2024.109097_bb0265","doi-asserted-by":"crossref","first-page":"1050","DOI":"10.1016\/j.amjmed.2009.03.032","article-title":"D-dimer testing in patients with suspected pulmonary embolism and impaired renal function","volume":"122","author":"Karami-Djurabi","year":"2009","journal-title":"Am. J. Med."},{"issue":"05","key":"10.1016\/j.thromres.2024.109097_bb0270","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1055\/s-0037-1598061","article-title":"Scoring systems for estimating the risk of anticoagulant-associated bleeding","volume":"43","author":"Parks","year":"2017","journal-title":"Semin Thromb Hemost. Thieme Medical Publishers"},{"issue":"10","key":"10.1016\/j.thromres.2024.109097_bb0275","first-page":"724","article-title":"How I assess and manage the risk of bleeding in patients treated for venous thromboembolism","volume":"135","author":"Klok","year":"2020","journal-title":"Blood. American Society of Hematology"},{"issue":"2","key":"10.1016\/j.thromres.2024.109097_bb0280","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1016\/j.cjca.2016.08.018","article-title":"Are existing risk scores for nonvalvular atrial fibrillation useful for prediction or risk adjustment in patients with chronic kidney disease?","volume":"33","author":"McAlister","year":"2017","journal-title":"Can. J. Cardiol."},{"issue":"9","key":"10.1016\/j.thromres.2024.109097_bb0285","first-page":"1558","article-title":"Bleeding risk assessment in end-stage kidney disease: validation of existing risk scores and evaluation of a machine learning-based approach","volume":"122","author":"Nopp","year":"2022","journal-title":"Thromb Haemost. Georg Thieme Verlag KG"},{"issue":"5","key":"10.1016\/j.thromres.2024.109097_bb0290","doi-asserted-by":"crossref","first-page":"1369","DOI":"10.1183\/13993003.00280-2016","article-title":"Prediction of bleeding events in patients with venous thromboembolism on stable anticoagulation treatment","volume":"48","author":"Klok","year":"2016","journal-title":"European Respiratory Journal. European Respiratory Society"},{"issue":"3","key":"10.1016\/j.thromres.2024.109097_bb0295","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1002\/rth2.12214","article-title":"Evaluation of the predictive value of the bleeding prediction score VTE-BLEED for recurrent venous thromboembolism","volume":"3","author":"Klok","year":"2019","journal-title":"Res Pract Thromb Haemost."},{"issue":"8","key":"10.1016\/j.thromres.2024.109097_bb0300","doi-asserted-by":"crossref","first-page":"1910","DOI":"10.1111\/jth.15776","article-title":"Management of bleeding risk in patients who receive anticoagulant therapy for venous thromboembolism: communication from the ISTH SSC Subcommittee on Predictive and Diagnostic Variables in Thrombotic Disease","volume":"20","author":"den Exter","year":"2022","journal-title":"J Thromb Haemost."},{"issue":"17","key":"10.1016\/j.thromres.2024.109097_bb0305","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.119.012646","article-title":"Anticoagulant prescribing for non-valvular atrial fibrillation in the veterans health administration","volume":"8","author":"Rose","year":"2019","journal-title":"J Am Heart Assoc."},{"key":"10.1016\/j.thromres.2024.109097_bb0310","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1186\/s12916-021-02067-5","article-title":"Prescribing of direct oral anticoagulants and warfarin to older people with atrial fibrillation in UK general practice: a cohort study","volume":"19","author":"Mitchell","year":"2021","journal-title":"BMC Med."},{"key":"10.1016\/j.thromres.2024.109097_bb0315","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1001\/jamacardio.2022.1292","article-title":"Efficacy and safety considerations with dose-reduced direct oral anticoagulants: a review","volume":"7","author":"Bikdeli","year":"2022","journal-title":"JAMA Cardiology [Internet]"},{"issue":"2","key":"10.1016\/j.thromres.2024.109097_bb0320","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1016\/j.ekir.2021.11.011","article-title":"Phase 2 study of the factor XI antisense inhibitor IONIS-FXIRx in patients With ESRD","volume":"7","author":"Walsh","year":"2022","journal-title":"Kidney Int Rep."},{"issue":"22","key":"10.1016\/j.thromres.2024.109097_bb0325","doi-asserted-by":"crossref","first-page":"2173","DOI":"10.1182\/blood.2021011725","article-title":"The contact activation inhibitor AB023 in heparin-free hemodialysis: results of a randomized phase 2 clinical trial","volume":"138","author":"Lorentz","year":"2021","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.thromres.2024.109097_bb0330","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.jdmv.2023.04.002","article-title":"Development of new anticoagulant in 2023: prime time for anti-factor XI and XIa inhibitors","volume":"48","author":"Bentounes","year":"2023","journal-title":"JMV-Journal de M\u00e9decine Vasculaire."},{"issue":"7","key":"10.1016\/j.thromres.2024.109097_bb0335","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1056\/NEJMoa2105872","article-title":"Abelacimab for prevention of venous thromboembolism","volume":"385","author":"Verhamme","year":"2021","journal-title":"N. Engl. J. Med."},{"issue":"2","key":"10.1016\/j.thromres.2024.109097_bb0340","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1001\/jama.2019.20687","article-title":"Effect of osocimab in preventing venous thromboembolism among patients undergoing knee arthroplasty: the FOXTROT randomized clinical trial","volume":"323","author":"Weitz","year":"2020","journal-title":"JAMA"},{"issue":"5","key":"10.1016\/j.thromres.2024.109097_bb0345","doi-asserted-by":"crossref","first-page":"1381","DOI":"10.1016\/j.jtha.2023.02.008","article-title":"Recommendation on the nomenclature for anticoagulants: updated communication from the international society on thrombosis and Haemostasis scientific and standardization Commitee on the control of anticoagulation","volume":"21","author":"Barnes","year":"2023","journal-title":"J. Thromb. Haemost."},{"key":"10.1016\/j.thromres.2024.109097_bb0350","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.thromres.2018.11.031","article-title":"Study of the bioaccumulation of tinzaparin in renally impaired patients when given at prophylactic doses - the STRIP study","volume":"174","author":"Projean","year":"2019","journal-title":"Thromb. Res."},{"issue":"9","key":"10.1016\/j.thromres.2024.109097_bb0355","doi-asserted-by":"crossref","first-page":"673","DOI":"10.7326\/0003-4819-144-9-200605020-00011","article-title":"Meta-analysis: low-molecular-weight heparin and bleeding in patients with severe renal insufficiency","volume":"144","author":"Lim","year":"2006","journal-title":"Ann Intern Med. American College of Physicians"},{"issue":"8","key":"10.1016\/j.thromres.2024.109097_bb0360","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1056\/NEJMct1206642","article-title":"Nonheparin anticoagulants for heparin-induced thrombocytopenia","volume":"368","author":"Kelton","year":"2013","journal-title":"N. Engl. J. Med."},{"issue":"11","key":"10.1016\/j.thromres.2024.109097_bb0365","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1136\/heartjnl-2016-309266","article-title":"Warfarin utilisation and anticoagulation control in patients with atrial fibrillation and chronic kidney disease","volume":"103","author":"Yang","year":"2017","journal-title":"Heart"},{"issue":"11","key":"10.1016\/j.thromres.2024.109097_bb0370","doi-asserted-by":"crossref","first-page":"2599","DOI":"10.2215\/CJN.02400311","article-title":"Warfarin in atrial fibrillation patients with moderate chronic kidney disease","volume":"6","author":"Hart","year":"2011","journal-title":"Clin J Am Soc Nephrol."},{"issue":"5","key":"10.1016\/j.thromres.2024.109097_bb0375","article-title":"Oral anticoagulant agents in patients with atrial fibrillation and CKD: a systematic review and pairwise network meta-analysis","volume":"78","author":"Su","year":"2021","journal-title":"American Journal of Kidney Diseases. Elsevier"},{"issue":"6","key":"10.1016\/j.thromres.2024.109097_bb0380","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1177\/1060028020967635","article-title":"Direct Oral anticoagulant use in chronic kidney disease and Dialysis patients With venous thromboembolism: A systematic Review of thrombosis and bleeding outcomes","volume":"55","author":"Cheung","year":"2021","journal-title":"Ann. Pharmacother."},{"issue":"11","key":"10.1016\/j.thromres.2024.109097_bb0385","article-title":"Direct oral anticoagulants versus warfarin for preventing stroke and systemic embolic events among atrial fibrillation patients with chronic kidney disease","volume":"11","author":"Kimachi","year":"2017","journal-title":"Cochrane Database Syst Rev."},{"issue":"2","key":"10.1016\/j.thromres.2024.109097_bb0390","volume":"140","author":"January","year":"2019","journal-title":"Circulation [Internet]"},{"issue":"5","key":"10.1016\/j.thromres.2024.109097_bb0395","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1016\/j.chest.2018.07.040","article-title":"Antithrombotic therapy for atrial fibrillation: CHEST guideline and expert panel report","volume":"154","author":"Lip","year":"2018","journal-title":"Chest"},{"issue":"4","key":"10.1016\/j.thromres.2024.109097_bb0400","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2020.2175","article-title":"Association between use of warfarin for atrial fibrillation and outcomes among patients With end-stage renal disease: A systematic Review and Meta-analysis","volume":"3","author":"Randhawa","year":"2020","journal-title":"JAMA Netw. Open"},{"issue":"6","key":"10.1016\/j.thromres.2024.109097_bb0405","doi-asserted-by":"crossref","first-page":"1474","DOI":"10.1681\/ASN.2020111566","article-title":"Safety and efficacy of vitamin k antagonists versus rivaroxaban in hemodialysis patients with atrial fibrillation: a multicenter randomized controlled trial","volume":"32","author":"De Vriese","year":"2021","journal-title":"Journal of the American Society of Nephrology: JASN"},{"issue":"10","key":"10.1016\/j.thromres.2024.109097_bb0410","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1002\/jhm.12926","article-title":"Safety and effectiveness of apixaban versus warfarin for acute venous thromboembolism in patients with end-stage kidney disease: A national cohort study","volume":"17","author":"Ellenbogen","year":"2022","journal-title":"J. Hosp. Med."},{"issue":"6","key":"10.1016\/j.thromres.2024.109097_bb0415","doi-asserted-by":"crossref","first-page":"926","DOI":"10.1055\/s-0041-1740254","article-title":"Effectiveness and safety of apixaban versus warfarin in venous thromboembolism patients with chronic kidney disease","volume":"122","author":"Cohen","year":"2022","journal-title":"Thromb Haemost."},{"issue":"8","key":"10.1016\/j.thromres.2024.109097_bb0420","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1056\/NEJMoa1207541","article-title":"Apixaban for extended treatment of venous thromboembolism","volume":"368","author":"Agnelli","year":"2013","journal-title":"N. Engl. J. Med."},{"issue":"13","key":"10.1016\/j.thromres.2024.109097_bb0425","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.1056\/NEJMoa1700518","article-title":"Rivaroxaban or aspirin for extended treatment of venous thromboembolism","volume":"376","author":"Weitz","year":"2017","journal-title":"N. Engl. J. Med."},{"issue":"9","key":"10.1016\/j.thromres.2024.109097_bb0430","doi-asserted-by":"crossref","DOI":"10.1016\/j.amjmed.2023.05.013","article-title":"Anticoagulation-associated adverse drug events in hospitalized patients across two time periods","volume":"136","author":"Fanikos","year":"2023","journal-title":"Am J Med."},{"issue":"18","key":"10.1016\/j.thromres.2024.109097_bb0435","first-page":"1735","article-title":"Low-dose edoxaban in very elderly patients with atrial fibrillation","volume":"383","author":"Okumura","year":"2020","journal-title":"New England Journal of Medicine [Internet]. Massachusetts Medical Society"},{"key":"10.1016\/j.thromres.2024.109097_bb0440","article-title":"Safety of switching from a vitamin K antagonist to a non-vitamin K antagonist oral anticoagulant in frail older patients with atrial fibrillation: results of the FRAIL-AF randomized controlled trial","volume":"27","author":"Joosten","year":"2023","journal-title":"Circulation"},{"issue":"4","key":"10.1016\/j.thromres.2024.109097_bb0445","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1055\/a-1981-1763","article-title":"Assessment of DOAC in GEriatrics (Adage Study): rivaroxaban\/apixaban concentrations and thrombin generation profiles in NVAF very elderly patients","volume":"123","author":"Foulon-Pinto","year":"2023","journal-title":"Thromb Haemost."},{"issue":"22","key":"10.1016\/j.thromres.2024.109097_bb0450","doi-asserted-by":"crossref","first-page":"3360","DOI":"10.1182\/bloodadvances.2018024489","article-title":"American Society of Hematology 2018 guidelines for management of venous thromboembolism: heparin-induced thrombocytopenia","volume":"2","author":"Cuker","year":"2018","journal-title":"Blood Adv."},{"issue":"1","key":"10.1016\/j.thromres.2024.109097_bb0455","doi-asserted-by":"crossref","first-page":"93","DOI":"10.3390\/ijms23010093","article-title":"Recent advances in anticoagulant treatment of immune thrombosis: a focus on direct oral anticoagulants in heparin-induced thrombocytopenia and anti-phospholipid syndrome","volume":"23","author":"Carr\u00e9","year":"2021","journal-title":"Int J Mol Sci."},{"issue":"5","key":"10.1016\/j.thromres.2024.109097_bb0460","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1097\/MCP.0b013e328285d6bf","article-title":"Subcutaneous unfractionated heparin for the treatment of venous thromboembolism","volume":"13","author":"Kearon","year":"2007","journal-title":"Curr. Opin. Pulm. Med."},{"issue":"9","key":"10.1016\/j.thromres.2024.109097_bb0465","doi-asserted-by":"crossref","first-page":"1906","DOI":"10.1046\/j.1538-7836.2003.00364.x","article-title":"Low-molecular-weight heparin for the long-term treatment of symptomatic venous thromboembolism: meta-analysis of the randomized comparisons with oral anticoagulants","volume":"1","author":"Iorio","year":"2003","journal-title":"J. Thromb. Haemost."}],"container-title":["Thrombosis Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0049384824002299?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0049384824002299?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,8,24]],"date-time":"2024-08-24T22:18:22Z","timestamp":1724537902000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0049384824002299"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9]]},"references-count":93,"alternative-id":["S0049384824002299"],"URL":"https:\/\/doi.org\/10.1016\/j.thromres.2024.109097","relation":{},"ISSN":["0049-3848"],"issn-type":[{"value":"0049-3848","type":"print"}],"subject":[],"published":{"date-parts":[[2024,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Anticoagulant therapy in renal insufficiency theme: Anticoagulation in complex situations","name":"articletitle","label":"Article Title"},{"value":"Thrombosis Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.thromres.2024.109097","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"109097"}}